Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | PIK3CA |
Variant | E453K |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | PIK3CA E453K lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). E453K results in increased phosphorylation of Akt and Mek1/2, enhanced cell survival, increased cell proliferation and migration, and is transforming in culture (PMID: 26627007, PMID: 29533785, PMID: 34779417). |
Associated Drug Resistance | |
Category Variants Paths |
PIK3CA mutant PIK3CA act mut PIK3CA E453K PIK3CA mutant PIK3CA exon8 PIK3CA E453K |
Transcript | NM_006218.4 |
gDNA | chr3:g.179210291G>A |
cDNA | c.1357G>A |
Protein | p.E453K |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_006218.4 | chr3:g.179210291G>A | c.1357G>A | p.E453K | RefSeq | GRCh38/hg38 |
XM_011512894 | chr3:g.179210291G>A | c.1357G>A | p.E453K | RefSeq | GRCh38/hg38 |
XM_006713658 | chr3:g.179210291G>A | c.1357G>A | p.E453K | RefSeq | GRCh38/hg38 |
NM_006218.3 | chr3:g.179210291G>A | c.1357G>A | p.E453K | RefSeq | GRCh38/hg38 |
XM_011512894.2 | chr3:g.179210291G>A | c.1357G>A | p.E453K | RefSeq | GRCh38/hg38 |
XM_006713658.5 | chr3:g.179210291G>A | c.1357G>A | p.E453K | RefSeq | GRCh38/hg38 |
NM_006218 | chr3:g.179210291G>A | c.1357G>A | p.E453K | RefSeq | GRCh38/hg38 |
XM_006713658.4 | chr3:g.179210291G>A | c.1357G>A | p.E453K | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA E453K | breast cancer | resistant | Buparlisib | Preclinical - Cell culture | Actionable | In a preclinical study, breast cancer cells expressing PIK3CA E453K demonstrated resistance to treatment with Buparlisib (BKM120) in culture (PMID: 29636477). | 29636477 |
PIK3CA E453K | lung squamous cell carcinoma | no benefit | Taselisib | Case Reports/Case Series | Actionable | In a Phase I (SWOG S1400B) trial, Taselisib (GDC-0032) treatment did not meet its primary endpoint for response rate in patients with lung squamous cell carcinoma harboring PIK3CA mutations, resulting in no response in a patient harboring PIK3CA E453K (PMID: 31158500; NCT02785913). | 31158500 |